Duncan Bellamy
Laboratory Research Assistant & DPhil Student
Having graduated with a BSc. Hons Medical Sciences from the University of Edinburgh, I developed an interest in infectious diseases during an internship at the Ifakara Health Institute in Tanzania. I went on to complete a Masters in the Control of Infectious Diseases at The London School of Hygiene and Tropical Medicine.
I have worked as a Research Assistant for the Jenner Institute for 2 and a half years working on Malaria and Outbreak Pathogen Vaccine Trials. In September 2019 I began a DPhil at the University of Oxford in Malaria Vaccinology identifying correlates of protection in Pre-Erythrocytic malaria vaccines.
During 2020, I have been heavily involved in Oxford University COVID vaccine trial, where I was part of the large immunology team looking at a variety of T-cell immune repsonses to SARS spike protein after vaccination.
Recent publications
-
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), The Lancet. Infectious diseases
-
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Journal article
Jenkin D. et al, (2022), The Lancet. Microbe, 3, e663 - e671
-
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Journal article
Waerlop G. et al, (2022), Frontiers in immunology, 13
-
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
Journal article
Sklar MJ. et al, (2021), PLOS ONE, 16, e0256980 - e0256980
-
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Journal article
Butler C. et al, (2021), Vaccines, 9, 851 - 851